[New treatments for heart failure?].
Treatment of chronic heart failure still needs to be improved. Blockade of ET-1 and TNF-alpha, as well as the combined inhibition of ACE and NE have demonstrated limited benefits, thus other strategies continue being evaluated. This article reviews current concepts regarding the blockade of arginine vasopressin receptors (AVP) and the selective inhibition of matrix metalloproteinases (MMPs). Results with AVP blockade in humans have been encouraging, whereas inhibitors of MMPs continue under preclinical experimental phases and are controversial.